A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and determine the maximum tolerated
dose of TAS-102 administered in combination with CPT-11 in patients with advanced
gastrointestinal tumors.